Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03 - Concepedia

Concepedia

Publication | Open Access

Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03

DOI Full Paper Access

162

Citations

22

References

2006

Year

Ulrich Herrlinger, Johannes Rieger, Dorothee Koch, Simon Loeser, Britta Blaschke, Rolf‐Dieter Kortmann, Joachim P. Steinbach, Thomas Hundsberger, Wolfgang Wick, Richard Meyermann,

Journal of Clinical Oncology

Abstract

The combination of lomustine, TMZ, and radiotherapy had acceptable toxicity and yielded promising survival data in patients with newly diagnosed GBM. MGMT gene-promoter methylation was a strong predictor of survival.

References

	Year	Citations

Page 1